Tokyo, Japan, 21st November 2012: Sekisui Medical Co. Ltd. (http://www.sekisuimedical.jp/english/), a leading contract research organization providing preclinical and safety toxicology & chemical testing globally and ViruSure GmbH (www.virusure.com) announced today their partnership to market the services of ViruSure in Japan. Through this partnership Sekisui Medical will act as the sole agent for promoting ViruSure services in Japan. To launch this new partnership, ViruSure will be performing a workshop together with Sekisui Medical on the virus and prion safety of biopharmaceuticals in Tokyo on December 11th 2012. This will enable Japanese companies the opportunity to learn firsthand of the services ViruSure is able to offer as well as providing a forum for the discussion of challenges around virus and prion safety testing.
ViruSure offers services in the areas of virus and prion safety testing for biopharmaceutical products, cell banking and cell bank characterization services and in vivo biosafety studies (adventitious agent testing, tumorigenicity testing, oncogenicity testing), which are highly valuable to pharma and biotech companies specializing on biological products (e.g. recombinant proteins, vaccines, human and animal derived biological products, cell based therapies).
”We are happy to partner with such a distinguished company as Sekisui Medical, who shares the same philosophy of quality and customer service that has made ViruSure successful” stated Andy Bailey, CEO and co-founder of ViruSure. “We look forward to offer our experience to assist Japanese biopharmaceutical companies in reaching their goals for pathogen safety testing”. The partnership is a natural fit, since both Sekisui Medical and ViruSure will help Japanese companies elevate their quality standards through their combined service offerings.
About Sekisui Medical Co. Ltd.
Sekisui Medical is composed of three businesses, Diagnostic, Pharmaceutical & Fine Chemicals and ADME & Tox. Research and is a Contract Research Organization (CRO) specializing in assisting in R & D of new drugs. The CRO business provides the drug development industry with various drug evaluation services related to pharmacokinetics from the drug discovery through FDA and MHLW application and post-marketing surveillance.
The CRO business offers services such as Screening, Pharmacological, synthesis of radiolabeled compounds, Safety, Pharmacokinetic and Clinical studies. Our services cover not only animal studies but pharmacokinetics in human to discover toxicity.
About ViruSure GmbH
ViruSure is a privately owned biotech company specializing in the virus and prion safety testing of biopharmaceutical products and cell banking / characterization services with a world wide client base. The company brings a wealth and breadth of expertise to ensure that biopharmaceutical companies meet all relevant pathogen safety testing requirements. Our goal is simple- to offer the highest level of quality, customer service and regulatory compliance for pathogen safety testing. Our state of the art facilities located in Vienna, Austria are validated and certified to both GMP and GLP standards and all testing services are supported by a state of the risk based quality management system which ensures we remain cutting edge partner dedicated to providing, first and foremost, a quality service to the biopharmaceutical industry. www.virusure.com